Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). PureTech Health's share price for the quarter that ended in Dec. 2025 was $16.64. PureTech Health's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 24.17 Mil. Therefore, PureTech Health's market cap for the quarter that ended in Dec. 2025 was $402.16 Mil.
PureTech Health's quarterly market cap
declined
from Dec. 2024 ($441.97 Mil) to Jun. 2025 ($414.43 Mil) and
declined
from Jun. 2025 ($414.43 Mil) to Dec. 2025 ($402.16 Mil).
PureTech Health's annual market cap
declined
from Dec. 2023 ($766.07 Mil) to Dec. 2024 ($441.97 Mil) and
declined
from Dec. 2024 ($441.97 Mil) to Dec. 2025 ($402.16 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. PureTech Health's Enterprise Value for Today is $167.75 Mil.
PureTech Health (OTCPK:PRTCY) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
PureTech Health Market Cap Related Terms
PureTech Health Market Cap Historical Data
* Premium members only.
The historical data trend for PureTech Health's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PureTech Health's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's Market Cap distribution charts can be found below:
* The bar in red indicates where PureTech Health's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
PureTech Health's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PureTech Health (PRTCY) has a Market Cap of $425.52 Mil as of Jun. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on PureTech Health and its competitors. According to the industry distribution chart, PureTech Health ranks #438 out of 1430 companies in the Biotechnology industry, placing it in the top 30.6%.
Is PureTech Health's Market Cap too high?
PureTech Health's current Market Cap is $425.52 Mil. The Biotechnology industry median Market Cap is 117.26. PureTech Health's value of $425.52 Mil is 262.9% above this industry median. Based on the distribution chart, PureTech Health ranks #438 out of 1430 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PureTech Health has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #438 out of 1430 companies for Market Cap. This puts PureTech Health in the upper half of its industry. The industry median Market Cap is 117.26. PureTech Health's value of $425.52 Mil is 262.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.26, based on 1,430 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PureTech Health's current Market Cap of $425.52 Mil is 262.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on PureTech Health and its competitors. For the Biotechnology industry, the median Market Cap is 117.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PureTech Health's current Market Cap is $425.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (PRTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $70.09, compared to a current price of $17.54 — trading 75% below its estimated fair value. The current Market Cap is $425.52 Mil and 262.9% above the Biotechnology industry median of 117.26. PureTech Health's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For PureTech Health (PRTCY), the current Market Cap is $425.52 Mil as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (PRTCY) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of $17.54 is trading 75% below its estimated GF Value™ of $70.09.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for PRTCY:
Market Cap: $425.52 Mil
GF Value™: $70.09 vs. price of $17.54 (75% below fair value)
Industry Position: 262.9% above the Biotechnology median (#438 of 1430)
No single metric tells the full story. See the PRTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
62GF Score
Get the complete analysis for PRTCY
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRTCY has been successfully added to your 
